GABA<sub>B</sub> receptors are the G-protein-coupled receptors for γ-aminobutyric acid (GABA), the main inhibitory neurotransmitter in the brain. GABA<sub>B</sub> receptors are promising drug targets for a wide spectrum of psychiatric and neurological disorders. Receptor subtypes exhibit no pharmacological differences and are based on the subunit isoforms GABA<sub>B1a</sub> and GABA<sub>B1b</sub>. GABA<sub>B1a</sub> differs from GABA<sub>B1b</sub> in its ectodomain by the presence of a pair of conserved protein binding motifs, the sushi domains (SDs). Previous work showed that selectively GABA<sub>B1a</sub> contributes to heteroreceptors at glutamatergic terminals, whereas both GABA<sub>B1a</sub> and GABA<sub>B1b</sub> contribute to autoreceptors at GABAergic terminals or to postsynaptic receptors. Here, we describe GABA<sub>B1j</sub>, a secreted GABA<sub>B1</sub> isoform comprising the two SDs. We show that the two SDs, when expressed as a soluble protein, bind to neuronal membranes with low nanomolar affinity. Soluble SD protein, when added at nanomolar concentrations to dissociated hippocampal neurons or to acute hippocampal slices, impairs the inhibitory effect of GABA<sub>B</sub> heteroreceptors on evoked and spontaneous glutamate release. In contrast, soluble SD protein neither impairs the activity of GABA<sub>B</sub> autoreceptors nor impairs the activity of postsynaptic GABA<sub>B</sub> receptors. We propose that soluble SD protein scavenges an extracellular binding partner that retains GABA<sub>B1a</sub>-release machinery. Soluble GABA<sub>B1</sub> isoforms like GABA<sub>B1j</sub> may therefore act as dominant-negative inhibitors of heteroreceptors and control the level of GABA<sub>B</sub>-mediated inhibition at glutamatergic terminals. Of importance for drug discovery, our data also demonstrate that it is possible to selectively impair GABA<sub>B</sub> heteroreceptors by targeting their SDs.
In addition to the membrane-bound GABA<sub>B1a</sub> and GABA<sub>B1b</sub> subunit isoforms, the GABA<sub>B1j</sub> gene produces several secreted isoforms that all include the SDs (14–16). Secreted isoforms containing SDs were also described for other receptors and shown to exert dominant-negative effects by scavenging the binding partners of the membrane-bound receptor (25, 26). Here, we identified a novel secreted GABA<sub>B1j</sub> isoform containing the SDs and addressed whether such soluble isoforms have the potential to block neuronal GABA<sub>B</sub> receptor functions in a dominant-negative manner.

**EXPERIMENTAL PROCEDURES**

**Characterization of GABA<sub>B1j</sub> cDNA and mRNA**—An oligo(dT) primed double-stranded cDNA made from the cortex/cerebellum of 7-day-old rats (34) was screened with a 32P-labeled SD-specific cDNA hybridization probe as described (27). For Northern blot analysis, total RNA was isolated from mouse brain and cultured mouse cortical neurons using TRIzol reagent (Invitrogen). In situ hybridization was performed as described previously (28) using digoxigenin-labeled GABA<sub>B1j</sub>-specific antisense RNA probes.

**GABA<sub>B1j</sub> Protein Expression**—Because a GABA<sub>B1j</sub>-specific antibody is lacking, we tagged GABA<sub>B1a</sub> and GABA<sub>B1j</sub> with the c-Myc epitope (29) and inserted the cDNAs into the expression vector pCI (Promega). Conditioned medium of transfected HEK293 cells (Lipofectamine 2000, Invitrogen) was collected after 48 h and used to immunoprecipitate secreted GABA<sub>B1j</sub> protein. Briefly, the medium was incubated with protein G-agarose (Roche Applied Science) for 2 h, precleared by centrifugation at 10,000 × g for 10 min, and incubated overnight with a monoclonal anti-Myc antibody (9E10, Sigma-Aldrich, diluted 1:1000) coupled to protein G-agarose. After five washes in radio immunoprecipitation assay buffer, and the lysate was precleared at 10,000 × g for 10 min and mixed with 2× SDS loading buffer, separated on SDS-PAGE, and analyzed by Western blotting. To control for GABA<sub>B1a</sub> and GABA<sub>B1j</sub> expression levels, transfected HEK293 cells were lysed in radio immunoprecipitation assay buffer, and the lysate was precleared at 10,000 × g for 10 min and mixed with 2× SDS loading buffer. For Western blot analysis, we used rabbit polyclonal anti-Myc (PRB-150C diluted 1:1000, Covance) and peroxidase-coupled secondary antibodies (donkey anti-rabbit diluted 1:2500, Amersham Biosciences) and exposed through a bipolar Pt-Ir electrode (25 μm, 2–5 V) delivered through a bipolar Pt-Ir electrode (25 μm in diameter) placed in the stratum radiatum. Miniature postsynaptic currents were recorded in the presence of tetrodotoxin (0.5 μM, Latoxan). For measuring miniature and evoked currents, patch electrodes (~3 megaohms) were filled with a solution containing, in mM: 30 cesium gluconate, 100 CsCl, 4 MgCl<sub>2</sub>, 10 creatine phosphate, 3.4 Na<sub>2</sub>ATP, 0.1 Na<sub>2</sub>GTP, 1.1 EGTA, and 5 Hepes (pH adjusted to 7.3 with KOH). Adenosine-mediated presynaptic inhibition was measured in the presence of CGP54626 (2 μM). For measuring Kir3 currents, cesium gluconate and CsCl were replaced by 130 mM potassium gluconate. GABAergic and glutamatergic currents were pharmacologically isolated using kynurenic acid (2 mM) and picrotoxin (100 μM), respectively. Neurons were clamped at −50 mV. Currents were amplified using a Cerenkov counting. Concentration response curves were generated from triplicate determinations (GraphPad).

**Electrophysiology**—300-μm-thick horizontal hippocampal slices were prepared from postnatal day 22–28 mice (VT 1000 vibrotome, Leica) into cooled artificial cerebro-spinal fluid (ACSF) (in mM: 119 NaCl, 2.5 KCl, 1.3 MgCl<sub>2</sub>, 2.5 CaCl<sub>2</sub>, 1.0 Na<sub>2</sub>H<sub>4</sub.PO<sub>4</sub>, 26.2 NaHCO<sub>3</sub>, and 11 glucose) equilibrated with 95% O<sub>2</sub>, 5% CO<sub>2</sub> at pH 7.3. After recovery for >1 h, slices were incubated for 6 h with RSDP (1.0 μg/ml), transferred to the recording chamber, and superfused (2 ml/min) with ACSF at 30–32 °C. Visualized whole cell voltage clamp recording was used to measure holding currents (Kir3 channels) and synaptic currents from the somata of CA1 pyramidal neurons. Synaptic currents were evoked by voltage pulses (100 μs, 2–5 V) delivered through a bipolar Pt-Ir electrode (25 μm in diameter) placed in the stratum radiatum. Miniature postsynaptic currents were recorded in the presence of tetrodotoxin (0.5 μM, Latoxan). For measuring miniature and evoked currents, patch electrodes (~3 megaohms) were filled with a solution containing, in mM: 30 cesium gluconate, 100 CsCl, 4 MgCl<sub>2</sub>, 10 creatine phosphate, 3.4 Na<sub>2</sub>ATP, 0.1 Na<sub>2</sub>GTP, 1.1 EGTA, and 5 Hepes (pH adjusted to 7.3 with KOH). Adenosine-mediated presynaptic inhibition was measured in the presence of CGP54626 (2 μM). For measuring Kir3 currents, cesium gluconate and CsCl were replaced by 130 mM potassium gluconate. GABAergic and glutamatergic currents were pharmacologically isolated using kynurenic acid (2 mM) and picrotoxin (100 μM), respectively. Neurons were clamped at −50 mV. Currents were amplified using a Cerenkov counting. Concentration response curves were generated from triplicate determinations (GraphPad).

**Electrophysiology**—300-μm-thick horizontal hippocampal slices were prepared from postnatal day 22–28 mice (VT 1000 vibrotome, Leica) into cooled artificial cerebro-spinal fluid (ACSF) (in mM: 119 NaCl, 2.5 KCl, 1.3 MgCl<sub>2</sub>, 2.5 CaCl<sub>2</sub>, 1.0 Na<sub>2</sub>H<sub>4</sub.PO<sub>4</sub>, 26.2 NaHCO<sub>3</sub>, and 11 glucose) equilibrated with 95% O<sub>2</sub>, 5% CO<sub>2</sub> at pH 7.3. After recovery for >1 h, slices were incubated for 6 h with RSDP (1.0 μg/ml), transferred to the recording chamber, and superfused (2 ml/min) with ACSF at 30–32 °C. Visualized whole cell voltage clamp recording was used to measure holding currents (Kir3 channels) and synaptic currents from the somata of CA1 pyramidal neurons. Synaptic currents were evoked by voltage pulses (100 μs, 2–5 V) delivered through a bipolar Pt-Ir electrode (25 μm in diameter) placed in the stratum radiatum. Miniature postsynaptic currents were recorded in the presence of tetrodotoxin (0.5 μM, Latoxan). For measuring miniature and evoked currents, patch electrodes (~3 megaohms) were filled with a solution containing, in mM: 30 cesium gluconate, 100 CsCl, 4 MgCl<sub>2</sub>, 10 creatine phosphate, 3.4 Na<sub>2</sub>ATP, 0.1 Na<sub>2</sub>GTP, 1.1 EGTA, and 5 Hepes (pH adjusted to 7.3 with KOH). Adenosine-mediated presynaptic inhibition was measured in the presence of CGP54626 (2 μM). For measuring Kir3 currents, cesium gluconate and CsCl were replaced by 130 mM potassium gluconate. GABAergic and glutamatergic currents were pharmacologically isolated using kynurenic acid (2 mM) and picrotoxin (100 μM), respectively. Neurons were clamped at −50 mV. Currents were amplified using a Cerenkov counting. Concentration response curves were generated from triplicate determinations (GraphPad).
RESULTS

GABA_B1j Encodes a Secreted Glycoprotein—To identify GABA_B1j isoforms, we screened a rat cortex/cerebellum cDNA library with an SD-specific hybridization probe. We isolated cDNAs for a novel isoform of ~1.6 kb that we named GABA_B1j. GABA_B1j diverges from GABA_B1a downstream of exon 4 and encodes a protein of 229 amino acids (Fig. 1A and supplemental Fig. 1A). The N-terminal 157 amino acids of GABA_B1j are identical to GABA_B1a and encode the signal peptide as well as the two SDs; the C-terminal 72 residues exhibit no significant homology to known proteins. Northern blot analysis revealed GABA_B1j transcripts of ~1.6 kb in brain tissue and cultured cortical neurons (Fig. 1B). An SD-specific hybridization probe demonstrated that GABA_B1j and GABA_B1a transcripts are of similar abundance (Fig. 1B). The GABA_B1j transcript distribution in brain sections (Fig. 1C) is similar to that described for GABA_B1a (32). Hydrophaticity analysis revealed that GABA_B1j protein lacks transmembrane domains (supplemental Fig. 1B).

Western blot analysis of transiently transfected HEK293 cells showed that the Myc-tagged GABA_B1j protein has a molecular mass of ~29 kDa (Fig. 1D). Deglycosylation of GABA_B1j with peptide N-glycosidase F decreased the molecular mass to ~23 kDa (data not shown), which corresponds to the calculated molecular weight of the mature protein. Immunoprecipitation experiments recovered GABA_B1j but not membrane-bound GABA_B1a from conditioned HEK293 cell-culture medium, demonstrating that GABA_B1j is a secreted protein (Fig. 1D). We next addressed whether endogenously expressed GABA_B1j protein is detectable in neurons. We did not succeed in generating a GABA_B1j-specific antibody; however, we generated an anti-SD monoclonal antibody that immunoprecipitates GABA_B1a protein from brain tissue (Fig. 1E, left panel). In addition, the antibody immunoprecipitates a protein with a molecular mass corresponding to that of GABA_B1j from metabolically labeled 1j probe.

FIGURE 1. Characterization of the GABA_B1j isoform. A, schematic representation of the 5' end of the GABA_B1j gene indicating the exons encoding the GABA_B1j, GABA_B1a, and GABA_B1b isoforms. GABA_B1j results from an 870-bp extension of exon 4 at its 3' end (exon 4'), generating an open reading frame of 687 nucleotides encompassing the two SDs. B, Northern blot analysis of GABA_B1a and GABA_B1j transcripts. Total RNA extracted from primary mouse cortical (ctx) neurons in culture or mouse brain was hybridized to the 32P-labeled probes indicated in A. The pan probe encodes part of the extracellular GABA binding domain and detects ~4.5-kb GABA_B1a and ~4.1-kb GABA_B1j transcripts (not resolved). The SD1/2 probe encodes the two SDs and detects GABA_B1j and ~1.6-kb GABA_B1a transcripts. The 1j probe detects 510 nucleotides at the 3' end of exon 4. C, in situ hybridization with the digoxigenin-labeled 1j probe. Top, horizontal section depicting the dorsal tier of the brain; bottom, high magnification of coronal section depicting lobules of the cerebellum. The locations of the CA1/3 field of hippocampus proper (CA1/3), dentate gyrus (DG), medial habenula (MH), and the granular layer (GL) and molecular layer (ML) of the cerebellum are indicated. Scale bars, 2 mm (top) and 200 μm (bottom). D, HEK293 cells expressing Myc-tagged GABA_B1a (Myc-1a) or GABA_B1j (Myc-1j) proteins. Conditioned medium (cond. med.) was subjected to immunoprecipitation with a rabbit anti-Myc antibody and analyzed in parallel with total cell lysate on Western blots using a mouse anti-Myc antibody. Membrane-bound GABA_B1j protein was selectively detected in the cell lysate, whereas secreted GABA_B1j protein was additionally detected in the cell-conditioned medium. E, left panel, the anti-SD monoclonal antibody 43H12 immunoprecipitates GABA_B1a but not GABA_B1j from mouse brain lysates. Immunoprecipitated GABA_B1j protein (IP anti-SD) was analyzed in parallel with total brain lysate (input) on Western blots using a pan GABA_B1a antibody (12). Right panel, the anti-SD monoclonal antibody 43H12 immunoprecipitates two proteins with a molecular mass corresponding to that of GABA_B1j (*) and GABA_B1a (**) from metabolically labeled cortical neurons. Radiolabeled proteins were revealed by autoradiography.
Secreted GABA<sub>B1</sub> Isoforms Impair GABA<sub>B</sub> Geteroreceptors

**FIGURE 2.** Specific binding sites for <sup>125</sup>I-Tyr-RSDP in rat cortex synaptic membranes. A, expression of RSDP in Pichia pastoris. Top, a schematic representation of RSDP containing the two SDs flanked by two tobacco etch virus cleavage sites (TEVs) and C-terminal c-Myc and polyhistidine (His<sub>6</sub>) tags. Bottom, recombinant protein identified on Western blots using anti-His<sub>6</sub> antibodies. RSDP is N-glycosylated as indicated by the shift from ~29 kDa to the calculated molecular mass of ~23 kDa after peptide N-glycosidase F (PNGaseF) treatment. RSDP is stable at 37 °C for at least 7 days (data not shown). B, <sup>125</sup>I-Tyr-RSDP (0.5 nM) binding to 20 μg of membranes from cortex, CHO-K1, and HEK293FT cells, in the absence or presence of 200 nM unlabeled RSDP. The inhibition curve was calculated using nonlinear regression. Data points are means ± S.E. from three independent experiments.

**FIGURE 3.** RSDP impairs GABA<sub>B</sub> receptor-mediated inhibition of spontaneous glutamate release in dissociated hippocampal neurons in culture. A, the percentage of inhibition of the mEPSC frequency by baclofen (100 μM) was assessed in individual neurons under control condition (ACSF, n = 5) and after incubation with 4 nM (n = 5) or 40 nM (n = 7) RSDP for the times indicated (for values, see supplemental Table S1). B, time course of the RSDP effect on the baclofen-induced mEPSC frequency inhibition in individual neurons (n = 5 per condition). C, summary histograms illustrating that incubation with 40 nM RSDP for 1 h impairs baclofen (bac)- but not adenosine (adeno)-mediated mEPSC frequency inhibition. Values are means ± S.E. of the percentage of inhibition of the mEPSC frequency (100 μM baclofen, ACSF, 88.6 ± 2.4%; n = 5; RSDP, 15.7 ± 3.2%; n = 5, ***, p < 0.001, Kolmogorov-Smirnov; 100 μM adenosine, ACSF, 70.2 ± 4.0%; n = 5; RSDP, 78.6 ± 2.7%; n = 5). D, representative mEPSC recordings under baseline conditions, during adenosine application, after washing with ACSF (wash), during baclofen application, and after antagonizing GABA<sub>B</sub> receptors with CGP54626. Recordings from one cell each incubated with ACSF or RSDP are shown.

Neuronal Membranes Exhibit High Affinity Binding Sites for the SDs—To address whether SDs interact with specific binding sites in neuronal membranes, we produced a truncated GABA<sub>B1j</sub> protein containing the two SDs but lacking the C-terminal 72 residues (Fig. 2A). This RSDP was radiolabeled with <sup>125</sup>I at tyrosine residues and used in competition binding experiments. Approximately half of the <sup>125</sup>I-Tyr-RSDP bound to rat cortex synaptic membranes was specifically displaced by unlabeled RSDP (Fig. 2B). No specific <sup>125</sup>I-Tyr-RSDP binding sites were detected in cell membranes of HEK293FT and CHO-K1 cells (Fig. 2B). Concentration-response curves revealed a half-maximal inhibition of <sup>125</sup>I-Tyr-RSDP binding at ~2 nM of unlabeled RSDP (n = 3, 95% confidence interval 1.1–3.4 nM; Fig. 2C).

RSDP Impairs GABA<sub>B</sub> Receptor-mediated Inhibition of Spontaneous Glutamate Release—GABA<sub>B</sub> heteroreceptors inhibit the spontaneous release of glutamate, likely by interfering with the release process downstream of Ca<sup>2+</sup> entry (7, 8, 22). We addressed whether exogenous application of RSDP to dissociated hippocampal neurons in culture exerts a dominant-negative effect on heteroreceptors by scavenging a binding partner of their GABA<sub>B1a</sub> subunits. Under control conditions in ACSF, the GABA<sub>B</sub> receptor agonist baclofen (100 μM) significantly reduced the frequency (Fig. 3, A and B) but not the amplitude (data not shown) of mEPSCs recorded from pyramidal neurons, consistent with a presynaptic mode of action. At 4 nM of RSDP, a maximal impairment is seen after 12 h (Fig. 3A). At 40 nM of RSDP, a partial impairment of presynaptic inhibition was observed as early as 10 min after RSDP application, whereas a near complete impairment was observed after 1 h (Fig. 3, A and B). This shows that the effect of RSDP is concentration-dependent. RSDP did not interfere with the inhibition of spontaneous glutamate release mediated by adenosine A<sub>1</sub> receptors (Fig. 3, C and D), which converge on the same effectors as GABA<sub>B</sub> receptors.
Secreted GABA$_{B_1}$ Isoforms Impair GABA$_{B_2}$ Geteroreceptors

RSDP Selectively Impairs GABA$_{B_{1(a,2)}}$ Receptors Located at Glutamatergic Terminals—We next investigated whether RSDP similarly impairs GABA$_{B_2}$ heteroreceptors in acute hippocampal slices. Under control conditions, baclofen significantly reduced the mEPSC frequency recorded from CA1 pyramidal neurons (Fig. 4A). Baclofen was ineffective in reducing the mEPSC frequency after incubation of slices with 40 nM RSDP (Fig. 4A). Baclofen is also described to inhibit the mIPSC frequency by acting at autoreceptors (5, 33). Although baclofen inhibited the frequency of mIPSC recorded from CA1 pyramidal neurons, RSDP was without effect on this inhibition (Fig. 4A). Likewise, RSDP did not alter the amplitude of Kir3 currents induced by baclofen in CA1 pyramidal neurons (9, 11, 22), demonstrating that RSDP has no effect on postsynaptic GABA$_{B_2}$ receptors (Fig. 4A). These data suggest that RSDP selectively interferes with the function of GABA$_{B_2}$ heteroreceptors, which incorporate the GABA$_{B_{1a}}$ subunit. However, GABA$_{B_{1a}}$ also contributes to autoreceptors and postsynaptic GABA$_{B_2}$ receptors (22–24). In the above experiments, RSDP effects on GABA$_{B_{1(a,2)}}$ autoreceptors or postsynaptic GABA$_{B_{1(a,2)}}$ receptors may remain undetected due to the concomitant action of GABA$_{B_{1(b,2)}}$ receptors at GABAergic terminals and postsynaptic sites. We therefore used hippocampal slices of 1$b^{-/-}$ mice to address whether RSDP interferes with the activity of GABA$_{B_{1(a,2)}}$ autoreceptors and postsynaptic GABA$_{B_{1(a,2)}}$ receptors. We found that in 1$b^{-/-}$ slices, RSDP neither impaired autoreceptor responses nor impaired baclofen-activated Kir3 currents (Fig. 4B). In contrast, RSDP strongly impaired heteroreceptor responses in 1$b^{-/-}$ slices (Fig. 4B), thus corroborating the data obtained in wild-type slices (Fig. 4A). RSDP was without effect on pre- and postsynaptic GABA$_{B_2}$ responses in 1$a^{-/-}$ mice, in which all GABA$_{B_2}$ receptors incorporate the GABA$_{B_{1b}}$ subunit (Fig. 4C). As a control, RSDP again failed to impair the actions of pre- and postsynaptic adenosine A1 receptors in all genotypes (Fig. 4, A–C). In summary, these results demonstrate that RSDP exclusively impairs GABA$_{B_{1(a,2)}}$ receptors located at glutamatergic terminals.

RSDP Impairs GABA$_{B_2}$ Receptor-mediated Inhibition of Evoked Glutamate Release—Activation of presynaptic GABA$_{B_2}$ receptors not only reduces the frequencies of mEPSCs and mIPSCs but also reduces the amplitudes of evoked EPSCs and IPSCs (7, 11, 22). The inhibitory effect of baclofen on spontaneous release is believed to be mechanistically distinct from its effect on evoked release (5, 7, 8, 34). It therefore was interesting to address whether the effect of RSDP on the control of spontaneous glutamate release generalizes to the evoked release. Specifically, we tested whether RSDP interferes with the baclofen-induced reduction in the amplitudes of evoked EPSCs recorded from CA1 pyramidal neurons (22). Incubation of acute hippocampal slices with 40 nM RSDP essentially abolished the reduction of the EPSC amplitudes by baclofen (Fig. 5, A and B). As a control, RSDP failed to induce the baclofen-induced reduction of IPSC amplitudes recorded from CA1 pyramidal neurons (Fig. 5, A and B). In contrast, RSDP did not affect the baclofen-induced reduction of postsynaptic GABA$_{B_2}$ receptors (Fig. 5, A and B).

The tertiary structure of the SDs, which is fixed by two conserved intramolecular disulfide bridges, is critical for function (20). We produced a mutRSDP with serine substitutions of the first and fourth cysteine in each SD, which precludes disulfide bond formation (supplemental Fig. 2). We found that incubation of slices with mutRSDP or RSDP that was kept in a reduced

---

**FIGURE 4.** RSDP selectively impairs GABA$_{B_{1(a,2)}}$ receptors located at glutamatergic terminals. A, the percentage of mEPSC and mIPSC frequency inhibition by baclofen (bac, 100 μM) and adenosine (adeno, 100 μM) under control condition (ACSF, white bars) and after incubation of acute hippocampal slices from wild-type (WT) mice with RSDP (40 nM, black bars) for 6 h. Baclofen was significantly less efficient in reducing the frequency of mEPSCs recorded from CA1 pyramidal neurons incubated with RSDP than from neurons incubated with ACSF (ACSF, 71.0 ± 5.4% inhibition, n = 5; RSDP, 7.6 ± 2.2% inhibition, n = 9; ***p < 0.001, Kolmogorov-Smirnov; see also supplemental Table S2). RSDP was without effect on adenosine-mediated mEPSC frequency inhibition (ACSF, 67.0 ± 3.3% inhibition, n = 5; RSDP, 67.0 ± 3.0% inhibition, n = 6; supplemental Table S2). As an additional control, RSDP was also without effect on the baseline mEPSC frequency or amplitude (for values, see supplemental Table S3). RSDP did not affect the baclofen- or adenosine-mediated inhibition of the mIPSCs frequency recorded from CA1 pyramidal neurons (for values, see supplemental Table S2). RSDP did not alter the amplitudes of Kir3 current responses induced by baclofen and adenosine in CA1 pyramidal neurons (n = 6 per condition). B, RSDP impairs the baclofen-mediated mEPSC frequency inhibition in 1b$^{-/-}$ mice (ACSF, 67.0 ± 3.0% inhibition; RSDP, 6.0 ± 2.0%; n = 4; ***p < 0.001, Kolmogorov-Smirnov). Incubation with RSDP had no effect on baclofen- or adenosine-mediated effects on the mEPSC frequency (for values, see supplemental Table S2) or on Kir3 current amplitudes (baclofen-induced Kir3 current responses were reduced in the 1b$^{-/-}$ when compared with wild-type mice, as described (22). C, baclofen failed to depress the mEPSC frequency in 1a$^{-/-}$ mice due to the lack of GABA$_{B_2}$ heteroreceptors in these mice (22). The basal mEPSC frequency in 1a$^{-/-}$ mice was increased (for values, see supplemental Table S3), as reported previously (22). RSDP was without effect on the baclofen- or adenosine-mediated inhibition of the mEPSC frequency (for values, see supplemental Table S2) or on Kir3 currents in 1a$^{-/-}$ mice. All values are means ± S.E.
Secreted GABA<sub>B1</sub> Isoforms Impair GABA<sub>B</sub> Geteroreceptors

**FIGURE 5.** RSDP selectively impairs the baclofen-induced decrease of evoked EPSC amplitudes in acute hippocampal slices. **A**, average traces (n = 100 events) depicting evoked EPSCs and IPSCs in CA1 pyramidal neurons before (black) and after inhibition (red) with baclofen (100 μM) or adenosine (100 μM). Recordings were after a 6-h incubation of slices with ACSF, RSDP (40 nM), reduced RSDP (treatment with 20 mM dithiothreitol for 2 h prior to slice application), and RSDP with mutated disulfide bridges (mutRSDP). **B**, summary histograms of the inhibition of EPSCs and IPSCs by baclofen (100 μM) and adenosine (100 μM) in CA1 pyramidal neurons. In the presence of RSDP, baclofen was less efficient in reducing EPSC amplitudes (ACSF, 85 ± 4% inhibition, n = 6; RSDP, 12.5 ± 3.5% inhibition, n = 6). RSDP did not impair the baclofen- or adenosine-mediated inhibition of evoked IPSCs. Values are means ± S.E.

DISCUSSION

In this study, we describe GABA<sub>B1j</sub>, a secreted GABA<sub>B1</sub> subunit isoform. GABA<sub>B1j</sub> like all secreted GABA<sub>B1</sub> isoforms (14–16), contains the SDs present in GABA<sub>B1a</sub>-Naturally occurring soluble SDs of other membrane-bound receptors were shown to exert physiologically relevant dominant-negative effects (25, 26). We therefore asked whether the SDs of secreted GABA<sub>B1</sub> isoforms could act similarly and scavenge a putative extracellular binding partner of the membrane-bound GABA<sub>B1a</sub> subunit. Consistent with this proposal, we found that RSDP, a recombinant protein consisting of the two SDs, binds with low nanomolar affinity to specific binding sites in neuronal membranes. We also found that RSDP interferes with the activity of GABA<sub>B1a</sub> heteroreceptors, whereas having no effect at GABA<sub>B1a</sub> autoreceptors or postsynaptic GABA<sub>B1a</sub> receptors. These results imply that functionally relevant SD binding sites exist at the cell surface of glutamatergic terminals. In this context, it is interesting to note that other neurotransmitter receptors were recently shown to bind to extracellular partners that regulate their synaptic localization and functions (35–37). In our experiments, the extracellular matrix protein fibulin-2, which binds to the first SD of GABA<sub>B1a</sub> (19), was without effect on heteroreceptor function. We did not observe that RSDP co-immunoprecipitates with GABA<sub>B1a</sub> after co-expression in HEK293 cells, suggesting that SDs do not recruit heteroreceptors through homophilic interactions either (data not shown). Therefore, the auxiliary factor binding to SDs of GABA<sub>B1a</sub> at the cell surface remains to be identified.

How are GABA<sub>B1</sub> heteroreceptors inactivated following RSDP exposure? First of all, we exclude that RSDP acts as a competitive antagonist of GABA<sub>B</sub> receptors because RSDP did not inhibit GABA<sub>B1a</sub> mediated Kir3 responses in HEK293 cells (data not shown), nor did it inhibit the function of GABA<sub>B1a</sub> autoreceptors or postsynaptic GABA<sub>B1a</sub> receptors in hippocampal slices (Fig. 4B). It also appears unlikely that GABA<sub>B1a</sub> receptors rapidly internalize as a consequence of disrupting an extracellular interaction since neuronal GABA<sub>B</sub> receptors do not efficiently internalize (38). Moreover, GABA<sub>B1a</sub> autoreceptors or postsynaptic GABA<sub>B1a</sub> receptors are not affected by RSDP, suggesting that GABA<sub>B1a</sub> receptors are functional in the absence of an SD interaction (Fig. 4B). Since heteroreceptor impairment is seen within minutes of RSDP application to dissociated hippocampal neurons in culture, we also consider it unlikely that RSDP interferes with the axonal delivery of GABA<sub>B1a</sub> receptors. Most likely, the extracellular binding partner of the SDs acts as a diffusion trap that keeps heteroreceptors and elements of the release machinery in close proximity. RSDP may scavenge the SD binding partner and thereby promote lateral diffusion of heteroreceptors. This may explain why RSDP concomitantly interferes with GABA<sub>B</sub> effectors involved in the inhibition of spontaneous and evoked release.

Our data show that secreted GABA<sub>B1</sub> isoforms like GABA<sub>B1j</sub> could, in principle, adjust the level of presynaptic inhibition at
glutamergic terminals. It therefore will be interesting to address whether the production of the various secreted GABA$_{b1}$ isoforms is regulated in response to physiological stimuli. Of importance, our findings may also be exploited therapeutically. Drug development in the GABAB field was largely hampered because receptor subtypes cannot be distinguished pharmacologically. For example, it would be desirable to selectively inhibit heteroreceptors to boost excitatory neurotransmission in patients with cognitive impairments (39). Our experiments now directly show that this is possible by targeting the SDs.

**Acknowledgments—We thank R. Seddik, H. R. Brenner, and K. Vogt for critical reading of the manuscript.**

**REFERENCES**

1. Bettler, B., Kaupmann, K., Mosbacher, J., and Gassmann, M. (2004) *Physiol. Rev.* **84**, 835–867.
2. Bowery, N. G., Bettler, B., Froestl, W., Gallagher, J. P., Marshall, F., Raiteri, M., Bonner, T. l., and Enna, S. J. (2002) *Pharmacol. Rev.* **54**, 247–264.
3. Couve, A., Moss, S. J., and Pangalos, M. N. (2001) *Mol. Cell. Neurosci.* **16**, 296–312.
4. Dunlap, K., and Fischbach, G. D. (1981) *J. Physiol. (Lond.)* **317**, 519–535.
5. Gassmann, M., Shaban, H., Vigot, R., Chacur, C., Barbieri, S., van der Putten, H., and Bettler, B. (2001) *Neuron* **9**, 919–927.
6. Yamada, J., Saitow, F., Satake, S., Kiyohara, T., and Konishi, S. (1999) *Neuropharmacology* **38**, 1743–1753.
7. Lüscher, C., Jan, L. Y., Stoffel, M., Malenka, R. C., and Nicoll, R. A. (1997) *Neuron* **19**, 687–695.
8. Marshall, F. H., Jones, K. A., Kaupmann, K., and Bettler, B. (1999) *Trends Pharmacol. Sci.* **20**, 396–399.
9. Schuster, V., Lüscher, C., Blanchet, C., Klix, N., Sansig, G., Klebs, K., Schmutz, M., Heid, J., Gentry, C., Urban, L., Fox, A., Spooren, W., Jaton, A. L., Viguera, J. M., Pozza, M.,Kelly, P. H., Mosbacher, J., Froestl, W., Käslin, E., Korn, R., Bischoff, S., Kaupmann, K., van der Putten, H., and Bettler, B. (2001) *Neuron* **31**, 47–58.
10. Marsh, A., Schubert, H., Humeau, Y., Herry, C., Cassasus, G., Shimogori, D., Ciocchi, S., Barbieri, S., van der Putten, H., Kaupmann, K., Bettler, B., and Luthi, A. (2002) *Nature Neurosci.* **5**, 12565–12573.
11. Lewis, J. L., Bandyopadhyay, S., Farb, D. H., and Russe, S. J. (2004) *J. Neurosci.* **24**, 6115–6126.
12. Hawrot, E., Yao, Y., Shi, Q. L., Norman, D., Kirkstad, J., and Barlow, P. N. (1998) *FEBS Lett.* **432**, 103–108.
13. BLEIN, S., GINHAM, R., Uhrin, D., Smith, B. O., SOARES, D. C., VELDT, S., McIlhinney, R. A., White, J. H., and Barlow, P. N. (2004) *J. Biol. Chem.* **279**, 48292–48306.
14. Soares, D. C., and Barlow, P. N. (2005) in *Structural Biology of the Complement System* (Morikis, D., and Lambris, J. N., eds) pp. 19–62, CRC Press, Taylor and Francis Group, Boca Raton.
15. Grace, C. R., Perrin, M. H., DiGruccio, M. R., Miller, C. L., River, E. J., Vale, W. W., and Riek, R. (2004) *Proc. Natl. Acad. Sci. U. S. A.* **101**, 12836–12841.
16. Froestl, W., Gallagher, M., Jenkins, H., Madrid, A., Melcher, T., Teichman, S., Mondadori, C. G., and Pearlman, R. (2004) *Biochem. Pharmacol.* **68**, 1479–1487.

**Secreted GABA$_{b1}$ Isoforms Impair GABA$_{b}$ Geteroreceptors**

17. Steiger, J. L., Bandyopadhyay, S., Farb, D. H., and Russe, S. J. (2004) *J. Neurosci.* **24**, 6115–6126.
18. Hawrot, E., Yao, Y., Shi, Q. L., Norman, D., Kirkstad, J., and Barlow, P. N. (1998) *FEBS Lett.* **432**, 103–108.
19. BLEIN, S., GINHAM, R., Uhrin, D., Smith, B. O., SOARES, D. C., VELDT, S., McIlhinney, R. A., White, J. H., and Barlow, P. N. (2004) *J. Biol. Chem.* **279**, 48292–48306.
20. Soares, D. C., and Barlow, P. N. (2005) in *Structural Biology of the Complement System* (Morikis, D., and Lambris, J. N., eds) pp. 19–62, CRC Press, Taylor and Francis Group, Boca Raton.
21. Grace, C. R., Perrin, M. H., DiGruccio, M. R., Miller, C. L., River, E. J., Vale, W. W., and Riek, R. (2004) *Proc. Natl. Acad. Sci. U. S. A.* **101**, 12836–12841.
22. Froestl, W., Gallagher, M., Jenkins, H., Madrid, A., Melcher, T., Teichman, S., Mondadori, C. G., and Pearlman, R. (2004) *Biochem. Pharmacol.* **68**, 1479–1487.